Sugi Predict

Sugi Predict / Compounds / Amthamine

Amthamine

Amthamine

SCHEMBL400272

Cc1nc(N)sc1CCN

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH2 P25021 12/20 1.00
▸ HRH4 Q9H3N8 6/20 1.00
▸ HRH1 P35367 4/20 1.00
▸ CYP1A2 P05177 1/20 1.00
▸ NOS1 P29475 1/20 0.48
▸ ALDH1A1 P00352 3/20 0.40
▸ HRH3 Q9Y5N1 3/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ GAA P10253 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ DRD2 P14416 2/20 0.38
▸ DRD3 P35462 2/20 0.38
▸ ADRB2 P07550 1/20 0.38
▸ CHRM2 P08172 1/20 0.38
▸ CHRM4 P08173 1/20 0.38
▸ ADRB1 P08588 1/20 0.38
▸ HTR1A P08908 1/20 0.38
▸ CHRM5 P08912 1/20 0.38
▸ ADRA2A P08913 1/20 0.38
▸ CHRM1 P11229 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Amthamine SCHEMBL7443757 0.98 HRH2 (0.96) HRH2HRH4HRH1CYP1A2NOS1
SCHEMBL7443479 0.88 HRH2 (0.78) HRH2HRH4HRH1CYP1A2NOS1
Hydrochloric Acid SCHEMBL7443747 0.86 HRH2 (0.75) HRH2HRH4HRH1CYP1A2NOS1
SCHEMBL5911593 0.83 HRH2 (0.70) HRH2HRH4HRH1CYP1A2NOS1
SCHEMBL11397758 0.81 HRH2 (0.68) HRH2HRH4HRH1CYP1A2NOS1
SCHEMBL259638 0.81 HRH2 (0.68) HRH2HRH4HRH1CYP1A2NOS1
SCHEMBL1244176 0.80 HRH2 (0.67) HRH2HRH4HRH1CYP1A2ALDH1A1
Bromide SCHEMBL11173485 0.79 HRH2 (0.66) HRH2HRH4HRH1CYP1A2NOS1
SCHEMBL5911625 0.79 HRH2 (0.66) HRH2HRH4HRH1CYP1A2NOS1
Hydrochloric Acid SCHEMBL7432356 0.78 HRH2 (0.64) HRH2HRH4HRH1CYP1A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2459227-B1 Prodrugs containing an aromatic amine connected by an amide bond to a carrier ASCENDIS PHARMA AS (DK) 2021-03-17 — — EP claimed
EP-2961730-A2 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XenoPort, Inc. (US) 2016-01-06 — — EP claimed
US-9173953-B2 Prodrugs containing an aromatic amine connected by an amido bond to a linker ASCENDIS PHARMA AS (DK) 2015-11-03 — — US claimed
US-20150158809-A9 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2015-06-11 — — US claimed
WO-2014134005-A2 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2014-09-04 — — WO claimed
US-20140243544-A1 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2014-08-28 — — US claimed
EP-1937652-B1 PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS AVENTIS PHARMA INC (US) 2014-07-30 — — EP claimed
CN-101486668-B Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof XENOPORT INC 2014-07-02 — — CN claimed
US-20130225412-A1 SILICON NANOCARRIER FOR DELIVERY OF DRUG, PESTICIDES AND HERBICIDES , AND FOR WASTE WATER TREATMENT SARDARI LODRICHE SOROUSH (IR) 2013-08-29 — — US claimed
US-8299291-B2 Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs XENOPORT, INC. (US) 2012-10-30 — — US claimed
US-20080227782-A1 PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS AVENTIS PHARMACEUTICALS INC (US) 2008-09-18 — — US claimed
EP-1937652-A1 PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS Aventis Pharmaceuticals Inc. (US) 2008-07-02 — — EP claimed
EP-1874356-A2 AMINERGIC PHARMACEUTICAL COMPOSITIONS AND METHODS Board of Trustees of Michigan State University (US) 2008-01-09 — — EP claimed
WO-2007041634-A1 PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS AVENTIS PHARMACEUTICALS INC. (US) 2007-04-12 — — WO claimed
WO-2006113485-A2 AMINERGIC PHARMACEUTICAL COMPOSITIONS AND METHODS BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2006-10-26 — — WO claimed
US-6274160-B1 ADMINISTERING TOPICALLY TO HYMAN EYE FORMULATION COMPRISING HISTAMINE H.SUB.2 AGONIST(S) EXCLUDING IMPROMIDINE IN A PHARMACEUTICALLY ACCEPTABLE CARRIER FOR THERAPY OF DRY EYE ALCON LABORATORIES, INC. 2001-08-14 — — US claimed
US-6225332-B1 TOPICALLY ADMINISTERING HISTAMINE H.SUB.2 AGONIST(S) FOR THERAPY OF OCULAR ALLERGY AND INFLAMMATION ALCON LABORATORIES, INC. 2001-05-01 — — US claimed
WO-1999020265-A1 COMPOSITIONS CONTAINING HISTAMINE H2 AGONISTS AND METHODS OF USE IN TREATING DRY EYE ALCON LABORATORIES, INC. (US) 1999-04-29 — — WO claimed
EP-0511271-A1 THIAZOLE DERIVATIVES CEDONA PHARMACEUTICALS B.V. (NL) 1992-11-04 — — EP claimed
WO-1991010656-A1 THIAZOLE DERIVATIVES CEDONA PHARMACEUTICALS B.V. (NL) 1991-07-25 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227782-A1 PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS HRH2, HRH1, LTC4S HRH2 1/4885HRH4 4/4885HRH1 2/4885
US-20150158809-A9 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS CPS1, CA7, NAAA HRH2 2802/4885HRH4 2419/4885HRH1 3250/4885
US-20140243544-A1 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS CPS1, CA7, NAAA HRH2 2802/4885HRH4 2419/4885HRH1 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.